Latest post
Cala Health, a San Francisco Bay Area-based leader in bioelectronic medicine, has secured $50 million in its latest funding round. The financing was co-led by Vertex Growth Fund and Nexus NeuroTech Ventures, with additional support from existing investors, including Johnson & Johnson Innovation – JJDC, GV (Google Ventures), Lux Capital, and Lightstone Ventures.
This significant investment will help Cala Health push the boundaries forward in efforts that can transform the treatment landscape for chronic diseases with non-invasive wearable therapies.
Transforming Chronic Disease Treatment
Cala Health, a firm founded in 2014, is at the cutting edge of neuromodulation therapies for chronic conditions. Its flagship product, the Cala kIQ system, is designed to treat essential tremors (ET) and Parkinson’s disease using Transcutaneous Afferent Patterned Stimulation (TAPS). ET is a very common movement disorder that affects millions worldwide; it causes involuntary tremors in the hands and is one of the conditions where the treatment options have traditionally been few.
The Cala kIQ system offers a groundbreaking solution to these challenges. This non-invasive, FDA-cleared wearable device works by delivering personalized nerve stimulation through the wrist to counteract tremors. By analyzing each patient’s unique tremor signature, the device provides targeted, customized therapy, significantly reducing tremor severity and offering patients a meaningful improvement in their daily lives.
Harnessing the New Funding for Growth
The $50 million raised in this funding round will enable Cala Health to accelerate its growth on multiple fronts:
- Market Expansion: The funds will be used to expand the reach and enhance the commercialization of the Cala kIQ system. Recently, the device has received positive Medicare coverage, and it is now more accessible to patients who rely on Medicare for healthcare. This is a big step in increasing patient access to Cala Health’s transformative therapy.
- Therapeutic Development: The company intends to utilize the funds raised to further expand its therapeutic pipeline. Cala Health will use the money to explore applications in other areas such as neurology, cardiology, and psychiatry. In addition, the company is advancing additional clinical trials to further strengthen the scientific evidence for TAPS therapy.
Being able to raise physician and patient awareness of non-invasive neuromodulation as a treatment option is another key focus. Cala Health strives to become the leader in this emerging field of bioelectronic medicine through recognition of its innovative therapies.
Leading in Bioelectronic Medicine
Cala Health operates at the nexus between neuroscience, consumer electronics, and medical device technology, developing wearable devices offering medical-grade efficacy without the requirement for invasive procedures or systemic drugs. This allows the company to pioneer a new, fast-emerging bioelectronic medicine space where there’s growing demand for noninvasive, patient-centric solutions to chronic conditions.
The Cala kIQ system, which delivers personalized therapy, is a real advance in the treatment of essential tremor. Cala Health is now strengthening its leadership position for wearable neuromodulation technology with the addition of Medicare coverage and increasing clinical validation.
Also read: Dutch Biotech Startup Citryll Raises €85 Million funding
Cala Health has already made clinical validation strides, including completing the largest therapeutic study for essential tremor in the United States. Such an achievement does not only add credibility to their technology but also showcases how much the company cares about improving the lives of patients living with chronic conditions.
Increasing Market Access and Advancing Clinical Evidence
Cala Health’s newly attained Medicare coverage for its TAPS therapy is a significant step towards greater patient access to the Cala kIQ system. Opening up Medicare coverage allows access for a much larger population, mainly the elderly, who could not be reached by earlier traditional treatments for tremors. Cala Health fills in a critical gap in this regard by providing an efficient, non-invasive option in place of an invasive procedure or pharmaceutical.
Also, the company aims to make more scientific evidence behind TAPS therapy, making it one of the established methods for the treatment of chronic diseases. Besides the ongoing clinical trials and development of therapeutic approaches, Cala Health is growing its pipeline of non-invasive treatments for different chronic diseases and increasing its impact on the space of bioelectronic medicines.
Future Perspective of Cala Health
As Cala Health continues to build on its momentum, the $50 million funding will play a critical role in helping the company scale its operations and broaden its market presence. The company’s vision of offering wearable, non-invasive therapies for chronic diseases is poised to redefine how conditions like essential tremor and Parkinson’s disease are managed. With such support from its investors and growing clinical evidence, Cala Health is now poised to expand access to its therapies and create long-term improvements in patients’ lives.
Also read: Spanish AgTech Startup HEMAV Raises €8M to Expand AI Solutions for Sustainable Farming
CEO Deanna Harshbarger said: “This funding will propel Cala Health’s commercialization trajectory, especially with the recent Medicare coverage for TAPS therapy. We are excited to broaden awareness among patients and physicians about this innovative, on-demand technology that can effectively address tremors and improve quality of life.”
Looking forward, Cala Health will continue its expansion of products and growth within the rapidly expanding bioelectronic medicine market. Focusing on patient-centered, non-invasive solutions, Cala Health is well-positioned to revolutionize the management of chronic diseases and offer new hope to millions of patients worldwide who are looking for safer, more effective treatment options.
For more information about Cala Health and its innovative therapies, visit the company’s official website.
